drugset / Trial / NCT04361825
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, multi-center phase II study of durvalumab and AZD6738 combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.
Timeline
- Start
- 2020-06-17
- Primary completion
- 2023-10-25
- Completion
- 2023-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 240 mg | Oral |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |